379 related articles for article (PubMed ID: 28771049)
21. Guidance for the treatment of deep vein thrombosis and pulmonary embolism.
Streiff MB; Agnelli G; Connors JM; Crowther M; Eichinger S; Lopes R; McBane RD; Moll S; Ansell J
J Thromb Thrombolysis; 2016 Jan; 41(1):32-67. PubMed ID: 26780738
[TBL] [Abstract][Full Text] [Related]
22. Italian intersociety consensus on DOAC use in internal medicine.
Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
[TBL] [Abstract][Full Text] [Related]
23. Critical Review and Update on the Treatment of Acute and Chronic Pulmonary Embolism.
Shapiro NL; Bhatt SH
J Pharm Pract; 2016 Feb; 29(1):35-45. PubMed ID: 26589472
[TBL] [Abstract][Full Text] [Related]
24. Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Samos M; Stanciakova L; Skornova I; Bolek T; Kovar F; Stasko J; Galajda P; Mokan M; Kubisz P
Curr Drug Metab; 2017; 18(7):643-650. PubMed ID: 28412907
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological management of pulmonary embolism.
Gouin B; Robert-Ebadi H; Righini M; Blondon M
Expert Opin Pharmacother; 2017 Jan; 18(1):79-93. PubMed ID: 27917690
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
27. Drug Treatment of Venous Thromboembolism in the Elderly.
Boey JP; Gallus A
Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
[TBL] [Abstract][Full Text] [Related]
28. Retrospective Analysis of Direct-Acting Oral Anticoagulants (DOACs) Initiation Timing and Outcomes After Thrombolysis in High- and Intermediate-Risk Pulmonary Embolism.
Wolfe A; Phillips A; Tierney DM; Melamed R; Qadri G; Lillyblad M; Smith C; St Hill C; Stenzel AE; Beddow D; Kirven J; Kethireddy R; Patel L
Clin Appl Thromb Hemost; 2023; 29():10760296231156414. PubMed ID: 36890702
[TBL] [Abstract][Full Text] [Related]
29. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
Voukalis C; Lip GY; Shantsila E
Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
[TBL] [Abstract][Full Text] [Related]
30. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
31. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
[TBL] [Abstract][Full Text] [Related]
33. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment.
Burnett AE; Mahan CE; Vazquez SR; Oertel LB; Garcia DA; Ansell J
J Thromb Thrombolysis; 2016 Jan; 41(1):206-32. PubMed ID: 26780747
[TBL] [Abstract][Full Text] [Related]
34. Direct Oral Anticoagulants for Pulmonary Embolism.
Pizzi R; Cimini LA; Ageno W; Becattini C
Hamostaseologie; 2024 Jun; 44(3):206-217. PubMed ID: 38467144
[TBL] [Abstract][Full Text] [Related]
35. Treatment of venous thromboembolism.
Wells PS; Forgie MA; Rodger MA
JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
[TBL] [Abstract][Full Text] [Related]
36. The value of inhibitors of factor Xa for the treatment of pulmonary embolism.
Prandoni P; Temraz S; Barbar S; Pesavento R; Taher A
Intern Emerg Med; 2014 Sep; 9(6):617-22. PubMed ID: 24871638
[TBL] [Abstract][Full Text] [Related]
37. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
38. Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism.
Granziera S; Hasan A; Cohen AA
Clin Appl Thromb Hemost; 2016 Apr; 22(3):209-21. PubMed ID: 26329910
[TBL] [Abstract][Full Text] [Related]
39. Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry.
Chopard R; Andarelli JN; Humbert S; Falvo N; Morel-Aleton M; Bonnet B; Napporn G; Kalbacher E; Obert L; Degano B; Cappelier G; Cottin Y; Schiele F; Meneveau N
Thromb Res; 2019 Feb; 174():27-33. PubMed ID: 30553162
[TBL] [Abstract][Full Text] [Related]
40. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
